# A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination

> **NCT05911048** · PHASE2 · NOT_YET_RECRUITING · sponsor: **WestVac Biopharma Co., Ltd.** · enrollment: 3100 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) (WSK-V101C)
- **BIOLOGICAL:** Recombinant COVID-19 vaccine(Sf9 Cell) (WSK-V101)

## Key facts

- **NCT ID:** NCT05911048
- **Lead sponsor:** WestVac Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-12-30
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 3100 (ESTIMATED)
- **Last updated:** 2024-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05911048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05911048, "A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05911048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*